1 |
CCR5
| [7] Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Viral protein interaction with cytokine and cytokine receptor, Toxoplasmosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis | D06670
D06670
|
Maraviroc
| [2] 46 46, 84 |
2 |
CCR5
| [7] Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Viral protein interaction with cytokine and cytokine receptor, Toxoplasmosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis | D09878
D09878
|
Cenicriviroc
| [1] 94 94 |
3 |
MAPK14
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
4 |
MAPK14
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
5 |
MTOR
| [26] Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Insulin resistance, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00753
D00753
|
Sirolimus
| [40] 2 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 |
6 |
MTOR
| [26] Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Insulin resistance, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D02714
D02714
|
Everolimus
| [9] 34 34, 67, 89, 96, 137, 157, 158, 228, 277 |
7 |
MTOR
| [26] Phospholipase D signaling pathway Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Insulin resistance, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06068
D06068
|
Temsirolimus
| [1] 13 13 |
8 |
IFNA1
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
9 |
IFNA1
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
10 |
IFNA2
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
11 |
IFNA2
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
12 |
IFNA4
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
13 |
IFNA4
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
14 |
IFNA5
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
15 |
IFNA5
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
16 |
IFNA6
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
17 |
IFNA6
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
18 |
IFNA7
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
19 |
IFNA7
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
20 |
IFNA8
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
21 |
IFNA8
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
22 |
IFNA10
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
23 |
IFNA10
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
24 |
IFNA13
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
25 |
IFNA13
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
26 |
IFNA14
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
27 |
IFNA14
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
28 |
IFNA16
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
29 |
IFNA16
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
30 |
IFNA17
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
31 |
IFNA17
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
32 |
IFNA21
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
33 |
IFNA21
| [15] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
34 |
NFKB1
| [47] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Lipid and atherosclerosis | D01146
D01146
|
Iguratimod
| [5] 46 46, 51, 53, 271, 300 |
35 |
PIK3CA
| [58] Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11011
D11011
|
Alpelisib
| [1] 138 138 |
36 |
PIK3CA
| [58] Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
37 |
PIK3CB
| [58] Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
38 |
PIK3CD
| [58] Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| [2] 53 53, 65 |
39 |
PIK3CD
| [58] Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11437
D11437
|
Parsaclisib
| [3] 35 35, 53, 61 |
40 |
PPP3CA
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
41 |
PPP3CA
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
42 |
PPP3CA
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
43 |
PPP3CA
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
44 |
PPP3CA
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| [2] 49 49, 222 |
45 |
PPP3CB
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
46 |
PPP3CB
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
47 |
PPP3CB
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
48 |
PPP3CB
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
49 |
PPP3CB
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| [2] 49 49, 222 |
50 |
PPP3CC
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
51 |
PPP3CC
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
52 |
PPP3CC
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
53 |
PPP3CC
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
54 |
PPP3CC
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| [2] 49 49, 222 |
55 |
PPP3R1
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
56 |
PPP3R1
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
57 |
PPP3R1
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
58 |
PPP3R1
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
59 |
PPP3R1
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| [2] 49 49, 222 |
60 |
PPP3R2
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
61 |
PPP3R2
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
62 |
PPP3R2
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
63 |
PPP3R2
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
64 |
PPP3R2
| [20] MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| [2] 49 49, 222 |
65 |
PRKCB
| [37] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, NF-kappa B signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Long-term depression, Inflammatory mediator regulation of TRP channels, Insulin secretion, Melanogenesis, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, Insulin resistance, Salivary secretion, Pancreatic secretion, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Leishmaniasis, Influenza A, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Non-small cell lung cancer | D11935
D11935
|
Enzastaurin
| [1] 168 168 |
66 |
MAPK11
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
67 |
MAPK11
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
68 |
MAPK13
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
69 |
MAPK13
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
70 |
MAP2K1
| [48] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| [1] 34 34 |
71 |
MAP2K1
| [48] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| [4] 2 2, 34, 279, 280 |
72 |
MAP2K1
| [48] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| [1] 280 280 |
73 |
MAP2K1
| [48] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| [1] 34 34 |
74 |
MAP2K1
| [48] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| [1] 34 34 |
75 |
MAP2K2
| [41] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| [1] 34 34 |
76 |
MAP2K2
| [41] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| [4] 2 2, 34, 279, 280 |
77 |
MAP2K2
| [41] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| [1] 280 280 |
78 |
MAP2K2
| [41] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| [1] 34 34 |
79 |
MAP2K2
| [41] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| [1] 34 34 |
80 |
RAF1
| [43] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
81 |
BCL2
| [23] Platinum drug resistance Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Measles, Human immunodeficiency virus 1 infection, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Small cell lung cancer, Lipid and atherosclerosis | D10679
D10679
|
Venetoclax
| [1] 28 28 |
82 |
RELA
| [47] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Lipid and atherosclerosis | D12181
D12181
|
Edasalonexent
| [1] 113 113 |
83 |
MAPK12
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
84 |
MAPK12
| [41] MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Inflammatory mediator regulation of TRP channels, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
85 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D00742
D00742
|
Etanercept
| [16] 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 |
86 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D00754
D00754
|
Thalidomide
| [20] 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
87 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
88 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D02597
D02597
|
Adalimumab
| [17] 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 |
89 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D02598
D02598
|
Infliximab
| [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
90 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| [8] 37 37, 46, 49, 96, 97, 107, 226, 271 |
91 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D04358
D04358
|
Golimumab
| [8] 46 46, 56, 84, 96, 97, 107, 270, 271 |
92 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D04687
D04687
|
Lenalidomide
| [8] 16 16, 26, 28, 34, 49, 284, 300, 331 |
93 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D05393
D05393
|
Pegsunercept
| [1] 46 46 |
94 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| [5] 28 28, 51, 85, 227, 331 |
95 |
TNF
| [41] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D09944
D09944
|
Ozoralizumab
| [1] 46 46 |
96 |
CXCR4
| [8] Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Viral protein interaction with cytokine and cytokine receptor, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human immunodeficiency virus 1 infection, Pathways in cancer | D08971
D08971
|
Plerixafor
| [5] 19 19, 20, 65, 285, 299 |
97 |
CASP9
| [24] Platinum drug resistance Platinum drug resistance, p53 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Thyroid hormone signaling pathway, Parkinson disease, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Legionellosis, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, Viral myocarditis, Lipid and atherosclerosis | D11195
D11195
|
Rimiducid
| [6] 19 19, 60, 65, 284, 285, 326 |
98 |
CD3D
| [8] Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
99 |
CD3D
| [8] Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D08959
D08959
|
Otelixizumab
| [1] 46 46 |
100 |
CD3E
| [8] Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
101 |
CD3E
| [8] Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D08959
D08959
|
Otelixizumab
| [1] 46 46 |
102 |
CD3E
| [8] Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D11463
D11463
|
Mosunetuzumab
| [1] 49 49 |
103 |
CD3G
| [7] Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
104 |
CD3G
| [7] Th1 and Th2 cell differentiation Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08959
D08959
|
Otelixizumab
| [1] 46 46 |
105 |
CD4
| [10] Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06356
D06356
|
Zanolimumab
| [1] 46 46 |